Drugs / 4SCAR DLL3 T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07180927 | Sep 2025 → Dec 2028 expected | brain glioblastoma | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4SCAR DLL3 T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07180927 ↗ |
| Known as | 4SCAR-DLL3 | “4SCAR-DLL3 T Cell Therapy treating DLL3 positive glioblastoma” NCT07180927 ↗ |
| Action | Deplete | “This expression pattern makes DLL3 an attractive target for precision CAR-T therapy treating brain tumors, which involves engineering a patient's own T cells to recognize and...” NCT07180927 ↗ |
| Modality | Cell therapy | “DLL3-specific CAR-T cell therapy” NCT07180927 ↗ |
| Route | Intravenous | “via intravenous route” NCT07180927 ↗ |